121 related articles for article (PubMed ID: 31252051)
1. New isoniazid derivatives with improved pharmaco-toxicological profile: Obtaining, characterization and biological evaluation.
Dragostin I; Dragostin OM; Samal SK; Dash S; Tatia R; Dragan M; Confederat L; Ghiciuc CM; Diculencu D; Lupușoru CE; Zamfir CL
Eur J Pharm Sci; 2019 Sep; 137():104974. PubMed ID: 31252051
[TBL] [Abstract][Full Text] [Related]
2. Isonicotinoylhydrazone analogs of isoniazid: relationship between superoxide scavenging and tuberculostatic activities.
Georgieva N; Gadjeva V
Biochemistry (Mosc); 2002 May; 67(5):588-91. PubMed ID: 12059780
[TBL] [Abstract][Full Text] [Related]
3. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.
Hearn MJ; Cynamon MH
J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045
[TBL] [Abstract][Full Text] [Related]
6. Hepatoprotective effect of isonicotinoylhydrazone SH7 against chronic isoniazid toxicity.
Georgieva N; Gadjeva V; Tolekova A; Dimitrov D
Pharmazie; 2005 Feb; 60(2):138-41. PubMed ID: 15739904
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Hearn MJ; Cynamon MH
Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-isoniazid conjugates: Synthesis, evaluation of tuberculostatic activity, biodegradability and toxicity.
Berezin AS; Skorik YA
Carbohydr Polym; 2015 Aug; 127():309-15. PubMed ID: 25965488
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
10. Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis.
Chen T; Li Q; Guo L; Yu L; Li Z; Guo H; Li H; Zhao M; Chen L; Chen X; Zhong Q; Zhou L; Wu T
Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():659-65. PubMed ID: 26478357
[TBL] [Abstract][Full Text] [Related]
11. [Experimental comparison of the tuberculostatic activities of INH, INHG and INHG-Na (author's transl)].
Orlowski EH; Rosenfeld M; Wolter H; Schunk R
Arzneimittelforschung; 1976; 26(3):409-16. PubMed ID: 989337
[TBL] [Abstract][Full Text] [Related]
12. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
14. New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Vavříková E; Polanc S; Kočevar M; Košmrlj J; Horváti K; Bosze S; Stolaříková J; Imramovský A; Vinšová J
Eur J Med Chem; 2011 Dec; 46(12):5902-9. PubMed ID: 22018878
[TBL] [Abstract][Full Text] [Related]
15. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid.
Unissa AN; Doss C GP; Kumar T; Swathi S; Lakshmi AR; Hanna LE
J Glob Antimicrob Resist; 2017 Dec; 11():57-67. PubMed ID: 28743650
[TBL] [Abstract][Full Text] [Related]
16. New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity.
Castelo-Branco FS; de Lima EC; Domingos JLO; Pinto AC; Lourenço MCS; Gomes KM; Costa-Lima MM; Araujo-Lima CF; Aiub CAF; Felzenszwalb I; Costa TEMM; Penido C; Henriques MG; Boechat N
Eur J Med Chem; 2018 Feb; 146():529-540. PubMed ID: 29407978
[TBL] [Abstract][Full Text] [Related]
17. Metal complexes of isonicotinylhydrazide and their antitubercular activity.
Ali M; Ahmed M; Hafiz S; Kamal M; Mumtaz M; Hanif M; Khan KM
Pak J Pharm Sci; 2017 Nov; 30(6(Supplementary)):2399-2403. PubMed ID: 29188776
[TBL] [Abstract][Full Text] [Related]
18. Insights on the Mechanism of Action of INH-C
Vila-Viçosa D; Victor BL; Ramos J; Machado D; Viveiros M; Switala J; Loewen PC; Leitão R; Martins F; Machuqueiro M
Mol Pharm; 2017 Dec; 14(12):4597-4605. PubMed ID: 29091448
[TBL] [Abstract][Full Text] [Related]
19. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
20. Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.
Kandler JL; Mercante AD; Dalton TL; Ezewudo MN; Cowan LS; Burns SP; Metchock B; ; Cegielski P; Posey JE
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
